The Lobular Breast Cancer Alliance (LBCA) welcomed Dr. Rinath Jeselsohn as the new chair of its Scientific Advisory Board (SAB) in July. Dr. Jeselsohn is an assistant professor of medicine at Harvard Medical School, an associate physician of medicine at Brigham and Women’s Hospital, as well as a medical oncologist at Dana-Farber Cancer Institute.
Dr. Jeselsohn has been engaged in breast cancer research for more than 10 years. She currently focuses on the mechanisms of treatment resistance and tumor progression in hormone receptor positive breast cancer. A practicing clinician, Dr. Jeselsohn is also the lead investigator for clinical trials that she designed based on findings from her research and with the goal of finding new treatments for those with breast cancer.
Watch Dr. Jeselsohn’s interview with LBCA Communications Director Colleen Fitzwater below and discover more about her research, why she joined the SAB, and what she looks forward to in her role as chair.
Dr. Jeselsohn succeeds Dr. Otto Metzger as chair in a role he held since February 2021. Dr. Metzger will continue as an active member of the SAB. We thank him for his service as chair. For more information about lobular breast cancer or to make a gift visit lobularbreastcancer.org.